F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen With the Antidepressant Response of Ketamine

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This conference abstract has been retracted at the request of author Maura Furey, with approval from the Society of Biological Psychiatry Executive Council, comprised of Mary L. Phillips, Scott L. Rauch, and Trey Sunderland. All other authors have been notified of this retraction. The retraction of this conference abstract has been requested due to multiple errors. The stated purpose of the study in the Background is not consistent with the actual purpose of the study as stated in the protocol and grant documents. Further, the purpose improperly references comparison with ketamine, when ketamine was not tested in this study. In the Results, the outcome of a secondary analysis is reported that is not specified and is contradictory to the primary finding of no significant effect. The first statement in the Conclusions is not supported by the data. In addition, the second statement in the Conclusions is inaccurate because mechanism of action was not assessed in this study, nor was ketamine studied or compared with scopolamine. Lastly, all authors did not review and approve this abstract prior to its submission.